Long-term Outcome of 525 Patients With Mycosis Fungoides and Sézary Syndrome
2003/07/01 by Youn H. Kim, Howard L. Liu, Serena Mraz-Gernhard +3 · 28 citations
Medicine · #Cutaneous lymphoproliferative disorders research #Lymphoma Diagnosis and Treatment #Histiocytic Disorders and Treatments
paper · doi:10.1001/archderm.139.7.857
Abstract
OBJECTIVES: To study and update the clinical characteristics and long-term outcome of our patients with mycosis fungoides (MF) and Sézary syndrome (SS), and to identify important clinical factors predictive of survival and disease progression. DESIGN: A single-center, retrospective cohort analysis. SETTING: Academic referral center for cutaneous lymphoma. PATIENTS: Five hundred twenty-five patients with MF and SS evaluated and managed at Stanford University Cutaneous Lymphoma Clinic, Stanford, Calif, from 1958 through 1999. MAIN OUTCOME MEASURES: We calculated long-term actuarial overall and disease-specific survivals and disease progression by the Kaplan-Meier method, and relative risk (RR) for survival calculated from expected survivals in control populations. RESULTS: The majority of our patients presented with T1 (30%) or T2 (37%) disease; 18% presented with T3 and 15% with T4 skin involvement. Forty-three percent of deaths were attributable to MF, primarily in patients with T3 or T4 disease. The patients with a more advanced T classification and clinical stage had a worse survival outcome. Except for patients with T1 or stage IA disease, the RR for death is greater in patients with MF than in a control population (RR, 2.2 in stage IB/IIA disease, 3.9 in stage IIB/III disease, and 12.8 in stage IV disease). Despite similar overall survival in patients with stage IB or IIA disease, their disease-specific survivals were significantly different (P =.006). The most significant clinical prognostic factors in the univariate analysis were patient age, TNM and B classifications, overall clinical stage groupings, and the presence or absence of extracutaneous disease. In the multivariate analysis, patient age, T classification, and the presence of extracutaneous disease were the most important independent factors. The risk for disease progression to a more advanced TNM or B classification, worse clinical stage, or death due to MF correlated with the severity of the initial T classification. The risk for development of extracutaneous disease also correlated with T classification; none of these patients had T1 disease when their extracutaneous disease was detected. CONCLUSIONS: Patients with MF and SS have varying risks for disease progression or death. The most important clinical predictive factors for survival include patient age, T classification, and the presence of extracutaneous disease. The significant disease-specific survival differences between different clinical stages validate the usefulness of the present MF clinical staging system of the National Cancer Institute.
Cited by
- Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides
- The optimal use of bexarotene in cutaneous T-cell lymphoma
- Staphylococcus aureusinduces drug resistance in cancer T cells in Sézary syndrome
- Immunopathogenesis and therapy of cutaneous T cell lymphoma. [europepmc]
- Lesional gene expression profiling in cutaneous T-cell lymphoma reveals natural clusters associated with disease outcome. [europepmc]
- A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sézary syndrome. [europepmc]
- Skin-resident T cells: the ups and downs of on site immunity. [europepmc]
- CD30 expression and proliferative fraction in nontransformed mycosis fungoides. [europepmc]
- Transcriptional profiles predict disease outcome in patients with cutaneous T-cell lymphoma. [europepmc]
- Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma. [europepmc]
- Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome). [europepmc]
- Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients. [europepmc]
- Romidepsin: a new drug for the treatment of cutaneous T-cell lymphoma. [europepmc]
- Long-term outcomes of 1,263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009. [europepmc]
- Humanization of an anti-CCR4 antibody that kills cutaneous T-cell lymphoma cells and abrogates suppression by T-regulatory cells. [europepmc]
- Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. [europepmc]
- Resident memory T cells in human health and disease. [europepmc]
- TCR sequencing facilitates diagnosis and identifies mature T cells as the cell of origin in CTCL. [europepmc]
- Genomic profiling of Sézary syndrome identifies alterations of key T cell signaling and differentiation genes. [europepmc]
- Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management. [europepmc]
- Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma. [europepmc]
- Benign T cells drive clinical skin inflammation in cutaneous T cell lymphoma. [europepmc]
- Targeting CD47 in Sézary syndrome with SIRPαFc. [europepmc]
- Environmental and Other Extrinsic Risk Factors Contributing to the Pathogenesis of Cutaneous T Cell Lymphoma (CTCL). [europepmc]
- Antibiotics inhibit tumor and disease activity in cutaneous T-cell lymphoma. [europepmc]
- Cellular origins and genetic landscape of cutaneous gamma delta T cell lymphomas. [europepmc]
- Cutaneous T-cell lymphomas: 2021 update on diagnosis, risk-stratification, and management. [europepmc]
- Cutaneous T-cell lymphomas: 2023 update on diagnosis, risk-stratification, and management. [europepmc]
Related